Business
Chief Strategy Officer and Board appointments
Allergy Therapeutics plc has announced the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director, effective January 30, 2026. Helge Weiner-Trapness brings over 30 years of experience from global investment banks, including HSBC Holdings plc, and will focus on driving the company's long-term international growth strategy, corporate development, and partnership strategy. Lawrence Allen Wang, with over 20 years in healthcare and investment roles, including CFO of Adicon Clinical Laboratories, Inc., will strengthen the board's expertise as the company pursues its ambition to become a global leader in allergy treatments and evaluates a potential dual listing on the Hong Kong Stock Exchange. Neither appointee currently holds shares in the company. Disclaimer*
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n\n \n\nAllergy Therapeutics plc\n(\"Allergy Therapeutics\" or the \"Company\" or \"Group\")\n \nAllergy Therapeutics announces the appointments of Helge Weiner-Trapness as Chief Strategy Officer and Executive Director, and Lawrence Allen Wang as Independent Non-Executive Director\n \n- Newly created Chief Strategy Officer role will drive long-term international growth strategy as Group advances next-generation pipeline and explores opportunities to deliver on global ambitions\n- Appointments strengthen Board, each bringing decades of expertise in their respective fields to support Company's ambition to become a global leader in allergy treatments\n \n30 January 2026 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, today announces the appointment of Helge Weiner-Trapness as Chief Strategy Officer. He also joins the Group's Board as an Executive Director.\n \nHelge has more than 30 years of experience across leading global investment banks in the US and Asia. He most recently served as Vice Chairman, Global Banking at HSBC Holdings plc (LSE: HSBA; HKG: 0005), one of the world's largest financial organisations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. He was a Founding Partner of Hong Kong-based Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. Earlier, he held senior roles at Barclays Bank, Asia Pacific Land, J.P. Morgan Securities and Goldman Sachs.\n \nIn his newly created role as Chief Strategy Officer, Helge will drive Allergy Therapeutics' long-term growth strategy, including corporate development, partnership strategy and portfolio prioritisation as Allergy Therapeutics advances its next-generation pipeline and explores opportunities to deliver on its global ambitions.\nHelge Weiner-Trapness, Chief Strategy Officer and Executive Director, said: \"Allergy Therapeutics has established a leading position in its core markets, with a significant portfolio and an innovative pipeline that present a strong platform for future growth. I am looking forward to working with the Board and management team to drive the ...